Filing Flows › Repligen (RGEN) › Q3 2026 › vs Q2 2026
Repligen (RGEN) Q3 2026 vs Q2 2026 (quarter over quarter)
Repligen's revenue rose $5.2M (+3%) from $204M in Q2 2026 to $209M in Q3 2026. The biggest changes: Product +$5.2M (+3%); Royalty and other revenue +$1K (+2%).
Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%, net loss $38.4M, operating cash flow $43.1M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 18.2% | 13.4% | +4.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product | $209M | $204M | $5.2M | +3% |
| Royalty and other revenue | $44K | $43K | $1K | +2% |
| Revenue | $209M | $204M | $5.2M | +3% |
| Other income, net | $2.7M | $177K | $2.6M | 15× |
| Net loss | $38.4M | −$5.0M | $43.4M | — |
| Costs & expenses | $250M | $204M | $46.2M | +23% |
| Operating costs | $239M | $190M | $48.7M | +26% |
| Income tax | $11.6M | $9.1M | $2.5M | +27% |
| Cost of revenue | $98.3M | $94.1M | $4.2M | +5% |
| Research & development | $14.4M | $14.4M | $18K | +0.1% |
| SG&A | $83.6M | $76.6M | $7.0M | +9% |
| Other operating costs | $42.5M | $5.0M | $37.5M | +746% |
| Operating cash sources | $81.5M | $27.8M | $53.8M | +194% |
| Depreciation & amortization | $19.1M | $19.1M | $62K | +0.3% |
| Share-based compensation | $9.4M | $8.0M | $1.3M | +17% |
| Working capital & other | $53.1M | $683K | $52.4M | 78× |
| Net loss absorbed | $38.4M | −$5.0M | $43.4M | — |
| Operating cash flow | $43.1M | $32.8M | $10.3M | +32% |
| Free cash flow (OCF − capex) | $38.2M | $27.4M | $10.7M | +39% |
| Capital expenditures | $4.9M | $5.3M | −$386K | -7% |
Questions
How much did Repligen's revenue grow quarter over quarter in Q3 2026?
Repligen's revenue rose $5.2M (+3%) from $204M in Q2 2026 to $209M in Q3 2026.
What drove Repligen's revenue change in Q3 2026?
Product +$5.2M (+3%); Royalty and other revenue +$1K (+2%).